Beyond Weight Loss, Semaglutide Unexpectedly Linked to Lower Fracture Risk

For many people with diabetes who need to lose weight, weight loss is usually good news, but bones may bear another cost. Rapid weight loss is sometimes accompanied by loss of bone density, and older adults are especially concerned that a single fall could turn into a long rehabilitation. Now, a large real-world study places semaglutide within this tension: it appears to help people lose more weight, yet did not show more fractures, and was instead linked to a lower fracture risk.

The results were presented at ENDO 2026, the annual meeting of the Endocrine Society in the United States. The research team analyzed medical data from a U.S. electronic health records database from January 2016 to December 2023, including 59,879 adults aged 18 and older who had type 2 diabetes, no prior fractures, and no use of osteoporosis medications.

Among them, 26,324 used semaglutide; another 33,555 used other common weight-loss or metabolic treatments, including dulaglutide, phentermine/topiramate, or bupropion/naltrexone, and had no history of semaglutide use. The researchers compared changes in body mass index and fracture records between the two groups, and found that the semaglutide group had a larger reduction in BMI but fewer total fractures: 794 fractures were recorded in the semaglutide group, compared with 1,045 in the control group.

Converted into a risk difference, semaglutide users had about a 15% lower fracture risk. This figure is notable because semaglutide is best known for lowering blood glucose and supporting weight loss, with brand names including Ozempic, Wegovy, and Rybelsus; if greater weight loss is not accompanied by an increase in fractures, it suggests that the relationship between GLP-1 receptor agonists and bone metabolism may be more complex than “less body weight, more fragile bones.”

However, the shape of this study also limits the questions it can answer. It is a retrospective cohort study that relies on existing medical records. It can show an association, but cannot prove that semaglutide itself protects bones. The patients’ age, disease severity, activity level, nutritional status, fall risk, and intensity of clinical follow-up in the two groups could all affect fracture outcomes; even if the study design can adjust for them as much as possible, it remains difficult to fully rule out unrecorded differences.

The study also did not provide complete details in the public abstract on bone density, muscle mass, vitamin D status, or different fracture sites. This information is quite important for understanding the mechanism: fracture risk depends not only on bone quality, but also involves muscle strength, balance, hypoglycemia, vision, and environmental safety. In other words, fewer fractures could stem from changes in the bones themselves, or could be related to overall metabolic improvement, changes in weight-bearing load, or differences in medical care.

Clinically, this study is more like a signal light than a rewrite of prescribing rules. Patients who are using or considering semaglutide should not therefore regard it on their own as a fracture-prevention drug; but when physicians arrange weight-loss treatment, they may have more reason to track bone health, muscle maintenance, and fall risk at the same time. The next step requires prospective studies that track bone density, body composition, and fracture events together, in order to determine whether this unexpected signal is a drug effect or a favorable association emerging from real-world data.